Keyphrases
Clinical High Risk
100%
Implanted Cardioverter Defibrillator
100%
Ranolazine
100%
Ventricular Fibrillation
77%
Implantable Defibrillator
55%
Placebo
44%
Ventricular Tachycardia
44%
Ventricular Tachycardia/ventricular Fibrillation
33%
Implantable Cardioverter-defibrillator Therapy
33%
Recurrent Ventricular Tachycardia
33%
High Risk
22%
Confidence Interval
22%
Hazard Ratio
22%
Implantable Cardioverter-defibrillator Shock
22%
Quality of Life
11%
Low Risk
11%
Treatment Effect
11%
Patient Treatment
11%
Endpoint Analysis
11%
Increased Mortality
11%
Placebo-controlled Clinical Trial
11%
Inappropriate Shock
11%
Ischemic Cardiomyopathy
11%
Nonischemic Cardiomyopathy
11%
Blinded Study
11%
Challenging Problems
11%
Twice a Day
11%
Cardiac Hospitalization
11%
Medicine and Dentistry
Ventricular Fibrillation
100%
Ventricular Tachycardia
100%
Implantable Automatic Defibrillator
100%
Ranolazine
100%
Defibrillator
100%
Placebo
50%
Hazard Ratio
20%
Cardiogenic Shock
10%
Shock (Circulatory)
10%
Controlled Clinical Trial
10%
Quality of Life
10%
Ischemic Cardiomyopathy
10%
Nonischemic Cardiomyopathy
10%
Treatment Effect
10%
Pharmacology, Toxicology and Pharmaceutical Science
Heart Ventricle Fibrillation
100%
Heart Ventricle Tachycardia
100%
Ranolazine
100%
Placebo
50%
Controlled Clinical Trial
10%
Nonischemic Cardiomyopathy
10%
Ischemic Cardiomyopathy
10%
Cardiogenic Shock
10%